Thursday, 5 November 2026European Markets

GETLINK SE And FORESTIERE EQUAT. Have A High Dividend Yield And Return On Equity In The Railroads Industry.

Loading stream...

(vianews) - getlink se (get.pa) is among this list of stock assets with the highest dividend rate and return on equity on the railroads industry.

financial asset price forward dividend yield return on equity
getlink se (get.pa) €15.11 3.23% 16.74%
forestiere equat. (fore.pa) €610.00 0.85% 1.11%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. getlink se (get.pa)

3.23% forward dividend yield and 16.74% return on equity

getlink se engages in the design, finance, construction, and operation of fixed link infrastructure and transport system in france. the company operates through eurotunnel, europorte, and eleclink segments. the eurotunnel segment operates three tunnels of a length of approximately 50 kilometres each under the english channel, as well as two terminals at folkestone in the united kingdom and the coquelles in france. it also provides passenger shuttle services for the transport of trucks, cars, motor homes, coaches, and other vehicles. in addition, this segment manages high-speed passenger trains and rail freights, as well as fixed equipment and related installations. the europorte segment offers a range of integrated rail freight services, including national and international haulage, local services for secondary lines, individual junction management, infrastructure maintenance, and wagon loading and unloading services. the eleclink segment engages in the construction and operation of a 1 gigawatt electricity interconnector between the france and great britain. getlink se also engages in third-party retail, telecommunication cables, training activity, and property businesses, as well as the sale of travel insurance products. the company was formerly known as groupe eurotunnel s.e. and changed its name to getlink se in april 2018. getlink se was founded in 1986 and is based in paris, france.

earnings per share

as for profitability, getlink se has a trailing twelve months eps of €0.66.

pe ratio

getlink se has a trailing twelve months price to earnings ratio of 22.89. meaning, the purchaser of the share is investing €22.89 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.74%.

more news about getlink se.

2. forestiere equat. (fore.pa)

0.85% forward dividend yield and 1.11% return on equity

la forestière equatoriale sa does not have any significant operations. the company is based in puteaux, france. la forestière equatoriale sa operates as a subsidiary of compagnie du cambodge.

earnings per share

as for profitability, forestiere equat. has a trailing twelve months eps of €1.74.

pe ratio

forestiere equat. has a trailing twelve months price to earnings ratio of 350.57. meaning, the purchaser of the share is investing €350.57 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 1.11%.

more news about forestiere equat..

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com